CRPS-1
Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate
Ambros Therapeutics; $125 million Series A; chronic pain; complex regional pain syndrome type 1; CRPS-1; neridronate; non-opioid analgesic; bisphosphonate; Vivek Ramaswamy; biotech financing